Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 top ...

Q2 2025 Management View CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AMT-130 towards potentially becoming the first ...

Qure (NASDAQ:QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

Investing.com - uniQure N.V. (NASDAQ: QURE) reported second quarter revenue that fell short of analyst expectations, though its loss per share was narrower than anticipated. The gene therapy company’s ...

uniQure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.

--uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced promising interim data, including up to 24 months of ...

UniQure N.V. QURE, a gene therapy company focused on developing therapies for patients with severe medical needs, said Thursday it’s planning a strategic overhaul that will cut 28% of its ...

With the value for uniQure close to $33/share, it represents a very attractive bargain, trading at below $6 recently. Find out why QURE stock is a Strong Buy.

Shares of UniQure tumbled 17% in premarket trading on Thursday, the day after it announced that CSL Behring would acquire exclusive commercialization rights to its gene-therapy program. UniQure ...

The stock price of uniQure, a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0.79 per share ...

The stock price of uniQure (NASDAQ:QURE), a gene therapy company, has seen a rise of 20% in a week, while it is up 10% over the last month. The recent rise can be attributed to its Q3 loss of $0. ...

AMSTERDAM (AP) — AMSTERDAM (AP) — UniQure NV (QURE) on Tuesday reported a loss of $37.7 million in its second quarter. On a per-share basis, the Amsterdam-based company said it had a loss of 69 cents.